Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Anagrelide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE3B known ✓ | Q13370 | 20/20 | 0.97 |
| ▸ | PDE3A known ✓ | Q14432 | 20/20 | 0.97 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.97 |
| ▸ | MEN1 | O00255 | 1/20 | 0.97 |
| ▸ | PDE2A | O00408 | 1/20 | 0.97 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.97 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | BLM | P54132 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Anagrelide SCHEMBL729172 | 0.99 | PDE3B (0.94) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL29491059 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL5060881 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9411 | 0.99 | PDE3B (1.00) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL9046734 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1449704 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1568712 | 0.97 | PDE3B (0.97) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL16335881 | 0.92 | PDE3B (0.87) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL1664162 | 0.91 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A | |
| Anagrelide SCHEMBL28341325 | 0.91 | PDE3B (0.85) | PDE3BPDE3AP2RY12MEN1PDE2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1530 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119039240-A | Preparation method of anagrelide Lei Er nitrogen heterocyclic impurity hydrochloride | 南京百泽医药科技有限公司 | 2024-11-29 | — | — | CN | claimed |
| EP-4444314-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | Sartar Therapeutics Oy (FI) | 2024-10-16 | — | — | EP | claimed |
| US-20240282425-A1 | AUTHENTICATION METHODS AND SYSTEMS FOR DISPENSED PRESCRIPTIONS | LOW GORDON KEITH (US) | 2024-08-22 | — | — | US | claimed |
| CN-118354773-A | Synergistic composition for the treatment of cancer | 萨达治疗公司 | 2024-07-16 | — | — | CN | claimed |
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | ACERTA PHARMA BV (NL) | 2024-07-04 | — | — | US | claimed |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | ACERTA PHARMA BV (NL) | 2024-06-06 | — | — | US | claimed |
| CN-117586268-A | Recovery refining method of anagrelide hydrochloride | 黑龙江天宏药业股份有限公司 | 2024-02-23 | — | — | CN | claimed |
| EP-4213815-A1 | LONG-TERM STABLE ANAGRELID CAPSULE COMPOSITION | Ilko Ilaç Sanayi Ve Ticaret A.S. (TR) | 2023-07-26 | — | — | EP | claimed |
| WO-2023105119-A1 | SYNERGISTIC COMPOSITIONS FOR USE IN THE TREATMENT OF CANCER | SARTAR THERAPEUTICS OY (FI) | 2023-06-15 | — | — | WO | claimed |
| WO-2023091964-A2 | COMPOSITIONS AND METHODS FOR THE INHIBITION OF TUMOR METASTASIS AND HORIZONTAL GENE TRANSFER | THE REGENTS OF THE UNIVERSITY OF COLORADO A BODY CORPORATE (US) | 2023-05-25 | — | — | WO | claimed |
| US-20040096499-A1 | Novel dosage form | TORRENT PHARMACEUTICALS LIMITED (IN) | 2004-05-20 | — | — | US | claimed |
| US-20040092592-A1 | Stabilized L-Arginine platelet aggregation inhibitory compositions and processes for making same | KAPLAN LEONARD L (US) | 2004-05-13 | — | — | US | claimed |
| US-20040062800-A1 | Sustained release pharmaceutical dosage forms with minimized ph dependent dissolution profiles | SUPERNUS PHARMACEUTICALS, INC | 2004-04-01 | — | — | US | claimed |
| EP-1353694-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | Schering Corporation (US) | 2003-10-22 | — | — | EP | claimed |
| EP-1351668-A1 | SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORMS WITH MINIMIZED PH DEPENDENT DISSOLUTION PROFILES | Shire Laboratories Inc. (US) | 2003-10-15 | — | — | EP | claimed |
| US-20030158261-A1 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | SUPERNUS PHARMACEUTICALS, INC. | 2003-08-21 | — | — | US | claimed |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | SCHERING CORPORATION | 2002-10-10 | — | — | US | claimed |
| WO-2002058676-A1 | SUSTAINED RELEASE PHARMACEUTICAL DOSAGE FORMS WITH MINIMIZED PH DEPENDENT DISSOLUTION PROFILES | SHIRE LABORATORIES, INC. (US) | 2002-08-01 | — | — | WO | claimed |
| WO-2002058734-A2 | COMBINATIONS OF STEROL ABSORPTION INHIBITOR(S) WITH BLOOD MODIFIER(S) FOR TREATING VASCULAR CONDITIONS | SCHERING CORPORATION (US) | 2002-08-01 | — | — | WO | claimed |
| US-6287599-B1 | Sustained release pharmaceutical dosage forms with minimized pH dependent dissolution profiles | SHIRE LABORATORIES, INC. | 2001-09-11 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240216380-A1 | BTK Inhibitors to Treat Solid Tumors Through Modulation of the Tumor Microenvironment | BTK, LYN, SYK | PDE3B 1793/4885PDE3A 2576/4885P2RY12 1624/4885 |
| US-20240180904-A1 | Methods of Treating Chronic Lymphocytic Leukemia and Small Lymphocytic Leukemia Using a BTK Inhibitor | BTK, LYN, SYK | PDE3B 829/4885PDE3A 1427/4885P2RY12 1101/4885 |
| US-20020147184-A1 | Combinations of sterol absorption inhibitor(s) with blood modifier(s) for treating vascular conditions | APOB, FABP2, CYP46A1 | PDE3B 173/4885PDE3A 287/4885P2RY12 3515/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.